Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspire Veterinary Partners, Inc. (NASDAQ: IVP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and registration statements. These documents offer detailed insight into IVP’s veterinary hospital operations, financial condition, risk factors, and capital structure.
Through recent Form 8-K filings, Inspire has reported material events such as notices from the Nasdaq Stock Market regarding minimum bid price compliance, the scheduling of a Nasdaq hearings panel review, changes in its independent registered public accounting firm, the issuance of senior convertible promissory notes, and equity issuances related to consulting agreements and debt cancellation. These filings explain key terms of financing arrangements, conversion features, and potential dilution, and they describe events of default and use of proceeds.
The company’s S-1 registration statements describe its business model as an owner and operator of veterinary hospitals across the United States, outline services offered at its clinics, and provide extensive risk factor disclosures covering profitability, acquisition strategy, regulatory exposure, internal controls, and listing considerations. Proxy materials on Schedule 14A detail matters submitted to stockholders, such as director elections and auditor ratification, and explain voting rights associated with Class A and Class B common stock.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand issues such as new debt or equity financings, changes in auditors, Nasdaq listing status, and governance matters. Users can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive financial statements and management discussion, and monitor 8-Ks for real-time updates on significant corporate events. Insider ownership and equity incentive information can be explored through proxy statements and related filings.
By using this page, investors and researchers can efficiently navigate Inspire Veterinary Partners’ SEC reporting history, compare successive filings, and see how the company’s financial and regulatory profile develops over time.
Inspire Veterinary Partners, Inc. reported that director Erinn Thomas-Mackey resigned from its board of directors, effective immediately on February 26, 2026. The company stated that her resignation was not related to any disagreement regarding its operations, policies, or practices.
The update focuses solely on this board change and confirms that she did not raise disputes about how the business is being run.
Inspire Veterinary Partners is registering up to 200,000,000 shares of Class A common stock for resale by a single selling stockholder. The shares come from two secured convertible promissory notes and related share consideration, so conversions and note-related issuances could significantly increase the public float.
The company operates 14 veterinary hospitals in nine states but has a history of losses, including a net loss of $14,264,261 in 2024 and an accumulated deficit of $36,350,281. As of December 31, 2024, it held $723,690 in cash and restricted cash, and its auditors raised substantial doubt about its ability to continue as a going concern. Inspire’s stock has been delisted from Nasdaq and now trades on the OTCQB at $0.01 per share, and authorized common shares were increased to 700,000,000, highlighting both financing needs and potential dilution for existing holders.
Inspire Veterinary Partners, Inc. is registering up to 200,000,000 shares of Class A common stock for resale by a single selling stockholder under a secured convertible notes financing. The shares include stock issued and issuable from a $975,000 First Note, a Second Note of up to $650,000, and related equity consideration.
The company will not receive any proceeds from the selling stockholder’s resale of these shares. As of this prospectus, 118,953,260 shares were outstanding, with a maximum of 318,953,260 shares outstanding if all registered shares are issued. Inspire Veterinary operates 14 veterinary hospitals across nine states and recently increased its authorized common stock to 700,000,000 shares.
The filing highlights recent challenges, including a Nasdaq delisting for failure to meet the minimum bid price, with trading moved to the OTCQB under the symbol “IVPR,” and substantial net losses of $14.3 million in 2024 and $14.8 million in 2023. Management and auditors express substantial doubt about the company’s ability to continue as a going concern given limited cash of $723,690 as of December 31, 2024 and the need to raise additional capital.
Inspire Veterinary Partners, Inc. announced that a Nasdaq Hearings Panel has denied its request to continue listing on Nasdaq after the company failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As a result, its common stock was suspended from trading on The Nasdaq Capital Market at the open on January 21, 2026 and will be delisted, with Nasdaq expected to file a Form 25 to remove the securities from listing and registration. The company has received approval for its common stock to trade on the OTCQB Venture Market under the symbol “IVPR,” where trading also began on January 21, 2026. Inspire Veterinary states that it intends to continue filing periodic reports with the SEC.
Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC on January 14, 2026. The company agreed to cancel
Inspire Veterinary Partners, Inc. has filed an S-1 to register up to 200,000,000 shares of Class A common stock for potential resale by a single selling stockholder, mainly tied to two secured convertible promissory notes and related share consideration. The company will not receive proceeds from any resale of these shares. If all securities are issued and converted, shares outstanding could rise from 118,953,260 to 318,953,260.
The business owns 14 small-animal veterinary hospitals across nine U.S. states and aims to grow through acquisitions. It remains unprofitable, with a 2024 net loss of $14,264,261, an accumulated deficit of $36,350,281 and cash and restricted cash of $723,690 as of December 31, 2024, leading auditors to highlight substantial doubt about its ability to continue as a going concern.
The company has received a Nasdaq delisting notice for failure to meet the minimum bid price, with a hearing held on January 13, 2026 and the outcome pending. Recent actions include increasing authorized common shares to 700,000,000, issuing stock to cancel portions of a prior note, and granting 9,450,000 shares under a consulting agreement, all of which add to potential dilution and highlight its reliance on equity-linked financing.
Inspire Veterinary Partners, Inc. reported that it has amended its Articles of Incorporation to significantly increase its authorized Class A common stock. The amendment, effective upon filing on January 9, 2026, raises the authorized Class A common shares from 100,000,000 to 700,000,000, while leaving the authorized Class B common and preferred stock unchanged. The change was approved by the board of directors and stockholders holding the requisite voting power and is documented in a Certificate of Amendment filed with the Nevada Secretary of State.
Inspire Veterinary Partners, Inc. entered into a securities purchase agreement with Manetto Hill Fund Series I LLC under which the company may issue up to
Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC on December 18, 2025. Under this deal, the company cancelled $150,000 of outstanding principal on a June 10, 2025 promissory note in exchange for 3,000,000 shares of Class A common stock, based on a price of $0.05 per share. This transaction reduces debt while increasing the company’s share count.
The exchange and related offer of securities were completed as an unregistered private placement, relying on exemptions from registration under Section 3(a)(9), Section 4(a)(2), and Rule 506(b) of Regulation D. The full terms are set out in the Cancellation and Exchange Agreement filed as an exhibit.